@article{ff6b1b22e0004841a1aa29891953715b,
title = "Automated electrocardiographic quantification of myocardial scar in patients undergoing primary prevention implantable cardioverter-defibrillator implantation: Association with mortality and subsequent appropriate and inappropriate therapies",
abstract = "Background: Myocardial scarring from infarction or nonischemic fibrosis forms an arrhythmogenic substrate. The Selvester QRS score has been developed to estimate myocardial scar from the 12-lead electrocardiogram. Objective: We aimed to assess the value of an automated version of the Selvester QRS score for the prediction of implantable cardioverter-defibrillator (ICD) therapy and death in patients undergoing primary prevention ICD implantation. Methods: Unselected patients undergoing primary prevention ICD implantation were included in this retrospective, observational, multicenter study. The QRS score was calculated automatically from a digital standard preimplantation 12-lead electrocardiogram and was correlated to the occurrence of death and appropriate and inappropriate shocks during follow-up. Analyses were performed in groups defined by QRS duration < 130 ms vs ≥ 130 ms. Results: Overall, 1047 patients (872 [83%] men; median age 64 years IQR [55-71]) with ischemic (648, 62%) or nonischemic (399, 38%) cardiomyopathy were included. The median QRS duration was 123 ms (interquartile range [IQR] 111–157 ms), and the median QRS score was 5 (IQR 2–8). The QRS duration was <130 ms in 59% and ≥130 ms in 41%. During a median follow-up of 45 months (IQR 24–72 months), a QRS score of ≥5 was independently associated with a significantly higher risk of mortality (hazard ratio [HR] 1.67; 95% confidence interval [CI] 1.05–2.66; P =.031) and appropriate (HR 1.83; 95% CI 1.07–3.14; P =.028) and inappropriate (HR 2.32; 95% CI 1.04–5.17; P =.039) shocks in patients with QRS duration ≥ 130 ms. No association of the QRS score and outcome was observed in patients with QRS duration < 130 ms (P >.05). Conclusion: The automatically calculated Selvester QRS score, an indicator of myocardial scar burden, predicts mortality and appropriate and inappropriate shocks in patients undergoing primary prevention ICD implantation with a prolonged QRS duration.",
keywords = "Cardiomyopathy, ECG, Heart failure, Implantable cardioverter-defibrillator, Risk stratification, Sudden cardiac death, Ventricular arrhythmia",
author = "Tobias Reichlin and Babken Asatryan and Vos, {Marc A} and Rik Willems and Huikuri, {Heikki V} and Junttila, {M Juhani} and Schl{\"o}gl, {Simon C} and Katerina Hnatkova and Schaer, {Beat A} and Marek Malik and Markus Zabel and Christian Sticherling",
note = "Funding Information: Dr Reichlin has received speaker/consulting honoraria or travel support from Abbott/SJM, AstraZeneca, Brahms, Bayer, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, Medtronic, Pfizer-BMS, and Roche, all for work outside the submitted study. He has received support for his institution{\textquoteright}s fellowship program from Abbott/SJM, Biosense Webster, Biotronik, Boston Scientific, and Medtronic for work outside the submitted study. Dr Vos is a co-PI on Netherlands Cardiovascular Research Initiative (CVON): Dutch Heart Foundation, Dutch Federation of University Medical Centers, Netherlands Organisation for Health Research and Development, and Royal Netherlands Academy of Science: CVON PREDICT 1 and 2 and has received grants from Holland Health: the Public-Private Partnership grant of the Dutch Heart Foundation together with Medtronic. Dr Willems reports research funding from Biotronik, Boston Scientific, and Medtronic; speakers and consultancy fees from Medtronic, Boston Scientific, Biotronik, Abbott, and MicroPort. He is supported as postdoctoral clinical researcher by the Fund for Scientific Research Flanders. Drs Hnatkova and Malik report a research grant from the British Heart Foundation for work outside the submitted study. Dr Schaer is a member of the speaker{\textquoteright}s bureau of Medtronic. Dr Sticherling reports grants from Biosense Webster and lecture fees from Medtronic, Biosense Webster, Boston Scientific, MicroPort, Pfizer, and Biotronik. The rest of the authors report no conflicts of interest. Funding Information: This work was supported by the Swiss Heart Foundation , Switzerland, and the European Community{\textquoteright}s Seventh Framework Programme FP7/2007-2013 under grant agreement no. 602299 , EU-CERT-ICD. Publisher Copyright: {\textcopyright} 2020 Heart Rhythm Society",
year = "2020",
month = oct,
doi = "10.1016/j.hrthm.2020.05.016",
language = "English",
volume = "17",
pages = "1664--1671",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "10",
}